Skip to main content
SANTEN PHARMACEUTICAL CO.,LTD. logo

SANTEN PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4536 ISIN · JP3336000009 LEI · 529900TPT3I7C17MIM03 T Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2024-06-25 Annual Report
Country JP Japan
Listing T 4536

About SANTEN PHARMACEUTICAL CO.,LTD.

https://www.santen.com/en

Santen Pharmaceutical Co., Ltd. is a global company specializing in ophthalmology. It is engaged in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. The company's portfolio includes prescription and over-the-counter pharmaceuticals that address a wide range of ophthalmic conditions. Serving patients, consumers, and medical professionals in over 60 countries, Santen aims to contribute to the realization of “Happiness with Vision” by providing valuable products and services worldwide.

Recent filings

Filing Released Lang Actions
有価証券報告書－第112期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard Japanese regulatory filing equivalent to the US 10-K, covering the full fiscal year (2023-04-01 to 2024-03-31) and submitted to the Kanto Local Finance Bureau. It contains comprehensive financial statements and corporate disclosures. FY 2024
2024-06-25 Japanese
臨時報告書
Board/Management Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director. Section 1, "提出理由" (Reason for Submission), explicitly states that the report is filed based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 9 of the Cabinet Office Ordinance on Disclosure of Corporate Information, due to the resignation of the Representative Director Chairman, Mr. Akira Kurokawa. Section 2 details the change in management position (Representative Director resignation). This content directly relates to changes in senior management/board members. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short, but it is the primary disclosure document itself, not an announcement of a report.
2024-03-25 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies the period covered: "第112期第３四半期（自 2023年10月１日 至 2023年12月31日）". It also includes confirmation statements by management regarding the appropriateness of the report's contents, referencing the Financial Instruments and Exchange Act ("金融商品取引法"). This structure strongly indicates a comprehensive financial report covering an interim period shorter than a year. This aligns directly with the definition of an Interim / Quarterly Report (Code: IR). The document is not merely an announcement of a report (RPA/RNS) but appears to be the core content or a significant portion thereof, confirming the results for the period.
2024-02-13 Japanese
四半期報告書－第112期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Santen Pharmaceutical Co., Ltd., covering the third quarter of the 112th fiscal period (October 1, 2023, to December 31, 2023). It contains detailed financial statements, management analysis (MDA), and key performance indicators, which are characteristic of an Interim/Quarterly Report (IR). 9M 2024
2024-02-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying the Second Quarter Report (Interim Report). It confirms the accuracy of the financial statements for the period ending September 30, 2023. Since it is a formal regulatory filing confirming the contents of an interim report, it falls under the category of Regulatory Filings (RNS) as it is a specific compliance document rather than the interim report itself.
2023-11-09 Japanese
四半期報告書－第112期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Santen Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis of financial conditions, and operating results for the second quarter of the 112th fiscal period (July 1, 2023, to September 30, 2023). This fits the definition of an Interim/Quarterly Report (IR). Q2 2023
2023-11-09 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.